{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:26:39Z","timestamp":1793330799945,"version":"4.5.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.eururo.2024.09.012","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T16:43:02Z","timestamp":1727714582000},"page":"110-122","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["FGFR Inhibition in Urothelial Carcinoma"],"prefix":"10.1016","volume":"87","author":[{"given":"Roger","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Linscott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James W.F.","family":"Catto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siamak","family":"Daneshmand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bishoy M.","family":"Faltas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish M.","family":"Kamat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua J.","family":"Meeks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Necchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Pradere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiel S.","family":"van der Heijden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bas W.G.","family":"van Rhijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohann","family":"Loriot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2024.09.012_b0005","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/nrclinonc.2016.139","article-title":"Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?","volume":"14","author":"Rosti","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.eururo.2024.09.012_b0010","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.09.012_b0015","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1200\/JCO.2017.74.7576","article-title":"Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer","volume":"36","author":"Ramalingam","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.09.012_b0020","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1016\/S0140-6736(16)32417-5","article-title":"HER2-positive breast cancer","volume":"389","author":"Loibl","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2024.09.012_b0025","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41392-020-00222-7","article-title":"FGF\/FGFR signaling in health and disease","volume":"5","author":"Xie","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.eururo.2024.09.012_b0030","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/s41571-018-0115-y","article-title":"Fibroblast growth factor receptors as treatment targets in clinical oncology","volume":"16","author":"Katoh","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.eururo.2024.09.012_b0035","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/jb\/mvq121","article-title":"Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease","volume":"149","author":"Itoh","year":"2011","journal-title":"J Biochem"},{"key":"10.1016\/j.eururo.2024.09.012_b0040","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s40291-023-00647-0","article-title":"Urothelial bladder cancer: genomic alterations in fibroblast growth factor receptor","volume":"27","author":"Bou Zerdan","year":"2023","journal-title":"Mol Diagn Ther"},{"key":"10.1016\/j.eururo.2024.09.012_b0045","doi-asserted-by":"crossref","unstructured":"Bladder cancer. Nat Rev Dis Primers 2023;9:5. https:\/\/doi.org\/10.1038\/s41572-023-00475-w.","DOI":"10.1038\/s41572-023-00475-w"},{"key":"10.1016\/j.eururo.2024.09.012_b0050","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/path.1202","article-title":"Frequent FGFR3 mutations in urothelial papilloma","volume":"198","author":"van Rhijn","year":"2002","journal-title":"J Pathol"},{"key":"10.1016\/j.eururo.2024.09.012_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102530","article-title":"Role of FGFR3 in bladder cancer: treatment landscape and future challenges","volume":"115","author":"Ascione","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.eururo.2024.09.012_b0060","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1158\/2159-8290.CD-13-0050","article-title":"Identification of targetable FGFR gene fusions in diverse cancers","volume":"3","author":"Wu","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.eururo.2024.09.012_b0065","doi-asserted-by":"crossref","first-page":"4586","DOI":"10.1158\/1078-0432.CCR-23-1283","article-title":"Clinical and genomic landscape of FGFR3-altered urothelial carcinoma and treatment outcomes with erdafitinib: a real-world experience","volume":"29","author":"Guercio","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2024.09.012_b0070","doi-asserted-by":"crossref","first-page":"25732","DOI":"10.1073\/pnas.2008017117","article-title":"Loss of UTX\/KDM6A and the activation of FGFR3 converge to regulate differentiation gene-expression programs in bladder cancer","volume":"117","author":"Barrows","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.eururo.2024.09.012_b0075","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.eururo.2023.05.037","article-title":"Proteogenomic characterization of bladder cancer reveals sensitivity to apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand in FGFR3-mutated tumors","volume":"85","author":"Groeneveld","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.09.012_b0080","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1158\/2326-6066.CIR-15-0274","article-title":"Molecular drivers of the non-T-cell-inflamed tumor microenvironment in urothelial bladder cancer","volume":"4","author":"Sweis","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.eururo.2024.09.012_b0085","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1038\/s41467-021-22465-w","article-title":"An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer","volume":"12","author":"Lindskrog","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.eururo.2024.09.012_b0090","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1038\/s41467-019-10873-y","article-title":"Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling","volume":"10","author":"Robinson","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.eururo.2024.09.012_b0095","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/path.5143","article-title":"FGFR3 mutation increases bladder tumourigenesis by suppressing acute inflammation","volume":"246","author":"Foth","year":"2018","journal-title":"J Pathol"},{"key":"10.1016\/j.eururo.2024.09.012_b0100","doi-asserted-by":"crossref","first-page":"4030","DOI":"10.1158\/0008-5472.CAN-23-1065","article-title":"FGFR3 alterations in bladder cancer stimulate serine synthesis to induce immune-inert macrophages that suppress T-cell recruitment and activation","volume":"83","author":"Ouyang","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2024.09.012_b0105","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1158\/0008-5472.CAN-21-2362","article-title":"FGFR3 destabilizes PD-L1 via NEDD4 to control T-cell-mediated bladder cancer immune surveillance","volume":"82","author":"Jing","year":"2022","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2024.09.012_b0110","doi-asserted-by":"crossref","first-page":"e169241","DOI":"10.1172\/JCI169241","article-title":"FGFR inhibition augments anti-PD-1 efficacy in murine FGFR3-mutant bladder cancer by abrogating immunosuppression","volume":"134","author":"Okato","year":"2024","journal-title":"J Clin Invest"},{"key":"10.1016\/j.eururo.2024.09.012_b0115","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.eururo.2019.06.025","article-title":"Fibroblast growth factor receptor 3 alterations and response to PD-1\/PD-L1 blockade in patients with metastatic urothelial cancer","volume":"76","author":"Wang","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.09.012_b0120","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.euo.2020.04.005","article-title":"Can patients with muscle-invasive bladder cancer and fibroblast growth factor receptor-3 alterations still be considered for neoadjuvant pembrolizumab? A comprehensive assessment from the updated results of the PURE-01 study","volume":"4","author":"Necchi","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2024.09.012_b0125","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1038\/s41591-021-01579-0","article-title":"Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial","volume":"27","author":"Powles","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.eururo.2024.09.012_b0130","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/path.2207","article-title":"FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer","volume":"213","author":"Tomlinson","year":"2007","journal-title":"J Pathol"},{"key":"10.1016\/j.eururo.2024.09.012_b0135","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1200\/JCO.2005.05.1771","article-title":"Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas","volume":"24","author":"Hern\u00e1ndez","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.09.012_b0140","first-page":"1265","article-title":"The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate","volume":"61","author":"van Rhijn","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2024.09.012_b0145","doi-asserted-by":"crossref","first-page":"5444","DOI":"10.1158\/1078-0432.CCR-05-0122","article-title":"FGFR3 and Tp53 mutations in T1G3 transitional bladder carcinomas: independent distribution and lack of association with prognosis","volume":"11","author":"Hern\u00e1ndez","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2024.09.012_b0150","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.juro.2011.09.008","article-title":"The FGFR3 mutation is related to favorable pT1 bladder cancer","volume":"187","author":"van Rhijn","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2024.09.012_b0155","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.eururo.2022.02.028","article-title":"Prognostic and predictive value of fibroblast growth factor receptor alterations in high-grade non-muscle-invasive bladder cancer treated with and without bacillus Calmette-Gu\u00e9rin immunotherapy","volume":"81","author":"Mayr","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.09.012_b0160","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrc3817","article-title":"Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity","volume":"15","author":"Knowles","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.eururo.2024.09.012_b0165","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1093\/annonc\/mdu390","article-title":"Phase I\/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors","volume":"25","author":"Soria","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2024.09.012_b0170","doi-asserted-by":"crossref","first-page":"3693","DOI":"10.1158\/1078-0432.CCR-13-0190","article-title":"Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer","volume":"19","author":"Andr\u00e9","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2024.09.012_b0175","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1158\/1535-7163.MCT-16-0589","article-title":"Discovery and pharmacological characterization of JNJ-42756493 (erdafitinib), a functionally selective small-molecule FGFR family inhibitor","volume":"16","author":"Perera","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.eururo.2024.09.012_b0180","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1158\/2159-8290.CD-15-1246","article-title":"High-level clonal FGFR amplification and response to FGFR inhibition in a translational clinical trial","volume":"6","author":"Pearson","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.eururo.2024.09.012_b0185","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1093\/annonc\/mdw170","article-title":"Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment","volume":"27","author":"Pouessel","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2024.09.012_b0190","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1200\/JCO.2016.67.2048","volume":"35","author":"Nogova","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.09.012_b0195","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1158\/2159-8290.CD-18-0229","article-title":"Efficacy of BGJ398, a fibroblast growth factor receptor 1\u20133 inhibitor, in patients with previously treated advanced urothelial carcinoma with FGFR3 alterations","volume":"8","author":"Pal","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.eururo.2024.09.012_b0200","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.2217\/fon-2021-1629","article-title":"Targeting FGFR3 alterations with adjuvant infigratinib in invasive urothelial carcinoma: the phase III PROOF 302 trial","volume":"18","author":"Pal","year":"2022","journal-title":"Future Oncol"},{"key":"10.1016\/j.eururo.2024.09.012_b0205","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1200\/JCO.21.02303","article-title":"FORT-1: phase II\/III study of rogaratinib versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma selected based on FGFR1\/3 mRNA expression","volume":"41","author":"Sternberg","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.09.012_b0210","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.09.012_b0215","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMoa2308849","article-title":"Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma","volume":"389","author":"Loriot","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.09.012_b0220","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.annonc.2023.09.3116","article-title":"Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer","volume":"35","author":"Catto","year":"2024","journal-title":"Ann Oncol"},{"issue":"Suppl 2","key":"10.1016\/j.eururo.2024.09.012_b0225","doi-asserted-by":"crossref","first-page":"S1343","DOI":"10.1016\/j.annonc.2023.10.110","article-title":"LBA104 First safety and efficacy results of the TAR-210 erdafitinib (erda) intravesical delivery system in patients (pts) with non\u2013muscle-invasive bladder cancer (NMIBC) with select FGFR alterations (alt)","volume":"34","author":"Vilaseca","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2024.09.012_b0230","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.euo.2022.05.005","article-title":"Intermediate-risk non-muscle-invasive bladder cancer: updated consensus definition and management recommendations from the International Bladder Cancer Group","volume":"5","author":"Tan","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2024.09.012_b0235","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.eururo.2017.01.021","article-title":"A functional genetic screen identifies the phosphoinositide 3-kinase pathway as a determinant of resistance to fibroblast growth factor receptor inhibitors in FGFR mutant urothelial cell carcinoma","volume":"71","author":"Wang","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.09.012_b0240","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1158\/1535-7163.MCT-15-1010","article-title":"Akt activation mediates acquired resistance to fibroblast growth factor receptor inhibitor BGJ398","volume":"16","author":"Datta","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.eururo.2024.09.012_b0245","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1158\/2159-8290.CD-12-0569","article-title":"Parallel RNA interference screens identify EGFR activation as an escape mechanism in FGFR3-mutant cancer","volume":"3","author":"Herrera-Abreu","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.eururo.2024.09.012_b0250","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.633410","article-title":"MET-Pyk2 axis mediates acquired resistance to FGFR inhibition in cancer cells","volume":"11","author":"Kitowska","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.eururo.2024.09.012_b0255","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1158\/0008-5472.CAN-23-1398","article-title":"Adipocyte precursor-derived NRG1 promotes resistance to FGFR inhibition in urothelial carcinoma","volume":"84","author":"Hosni","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2024.09.012_b0260","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1593\/neo.121106","article-title":"The N550K\/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors","volume":"15","author":"Byron","year":"2013","journal-title":"Neoplasia"},{"key":"10.1016\/j.eururo.2024.09.012_b0265","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1158\/2159-8290.CD-16-1000","article-title":"Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion\u2013positive cholangiocarcinoma","volume":"7","author":"Goyal","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.eururo.2024.09.012_b0270","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.annonc.2023.10.794","article-title":"Pemigatinib for metastatic or surgically unresectable urothelial carcinoma with FGF\/FGFR genomic alterations: final results from FIGHT-201","volume":"35","author":"Necchi","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2024.09.012_b0275","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1158\/2159-8290.CD-22-1441","article-title":"Resistance to selective FGFR inhibitors in FGFR-driven urothelial cancer","volume":"13","author":"Facchinetti","year":"2023","journal-title":"Cancer Discov"},{"issue":"6 Suppl","key":"10.1016\/j.eururo.2024.09.012_b0280","article-title":"Phase Ib trial of erdafitinib (E) combined with enfortumab vedotin (EV) following platinum and PD-1\/L1 inhibitors for metastatic urothelial carcinoma (mUC) with FGFR2\/3 genetic alterations (GAs)","volume":"40","author":"Jain","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.09.012_b0285","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/s41585-023-00725-2","article-title":"Circulating and urinary tumour DNA in urothelial carcinoma\u2014upper tract, lower tract and metastatic disease","volume":"20","author":"Rose","year":"2023","journal-title":"Nat Rev Urol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283824026058?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283824026058?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T15:41:31Z","timestamp":1737646891000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283824026058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":57,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S0302283824026058"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2024.09.012","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"FGFR Inhibition in Urothelial Carcinoma","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2024.09.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}